Melatonin therapy in patients with Alzheimer’s disease

Autores
Cardinali, Daniel Pedro; Vigo, Daniel Eduardo; Olivar, Natividad; Vidal, Maria Florencia; Brusco, Luis Ignacio
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD.
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Olivar, Natividad. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Vidal, Maria Florencia. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Brusco, Luis Ignacio. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
MELATONIN
ALZHEIMER'S DISEASE
NEURODEGENERATION
FREE RADICALS
OXIDATIVE STRESS
AGING
MILD COGNITIVE IMPAIRMENT
MELATONIN ANALOGS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/16879
Acceder
id CONICETDig_f6a3c77de3422e3a495e3d556002849d
oai_identifier_str oai:ri.conicet.gov.ar:11336/16879
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Melatonin therapy in patients with Alzheimer’s diseaseCardinali, Daniel PedroVigo, Daniel EduardoOlivar, NatividadVidal, Maria FlorenciaBrusco, Luis IgnacioMELATONINALZHEIMER'S DISEASENEURODEGENERATIONFREE RADICALSOXIDATIVE STRESSAGINGMILD COGNITIVE IMPAIRMENTMELATONIN ANALOGShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD.Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaFil: Olivar, Natividad. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Vidal, Maria Florencia. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Brusco, Luis Ignacio. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMultidisciplinary Digital Publishing Institute2014-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/16879Cardinali, Daniel Pedro; Vigo, Daniel Eduardo; Olivar, Natividad; Vidal, Maria Florencia; Brusco, Luis Ignacio; Melatonin therapy in patients with Alzheimer’s disease; Multidisciplinary Digital Publishing Institute; Antioxidants; 3; 2; 4-2014; 245-2772076-3921enginfo:eu-repo/semantics/altIdentifier/url/http://www.mdpi.com/2076-3921/3/2/245info:eu-repo/semantics/altIdentifier/doi/10.3390/antiox3020245info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:04:02Zoai:ri.conicet.gov.ar:11336/16879instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:04:02.338CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Melatonin therapy in patients with Alzheimer’s disease
title Melatonin therapy in patients with Alzheimer’s disease
spellingShingle Melatonin therapy in patients with Alzheimer’s disease
Cardinali, Daniel Pedro
MELATONIN
ALZHEIMER'S DISEASE
NEURODEGENERATION
FREE RADICALS
OXIDATIVE STRESS
AGING
MILD COGNITIVE IMPAIRMENT
MELATONIN ANALOGS
title_short Melatonin therapy in patients with Alzheimer’s disease
title_full Melatonin therapy in patients with Alzheimer’s disease
title_fullStr Melatonin therapy in patients with Alzheimer’s disease
title_full_unstemmed Melatonin therapy in patients with Alzheimer’s disease
title_sort Melatonin therapy in patients with Alzheimer’s disease
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
Olivar, Natividad
Vidal, Maria Florencia
Brusco, Luis Ignacio
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
Olivar, Natividad
Vidal, Maria Florencia
Brusco, Luis Ignacio
author_role author
author2 Vigo, Daniel Eduardo
Olivar, Natividad
Vidal, Maria Florencia
Brusco, Luis Ignacio
author2_role author
author
author
author
dc.subject.none.fl_str_mv MELATONIN
ALZHEIMER'S DISEASE
NEURODEGENERATION
FREE RADICALS
OXIDATIVE STRESS
AGING
MILD COGNITIVE IMPAIRMENT
MELATONIN ANALOGS
topic MELATONIN
ALZHEIMER'S DISEASE
NEURODEGENERATION
FREE RADICALS
OXIDATIVE STRESS
AGING
MILD COGNITIVE IMPAIRMENT
MELATONIN ANALOGS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD.
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Olivar, Natividad. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Vidal, Maria Florencia. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Brusco, Luis Ignacio. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD.
publishDate 2014
dc.date.none.fl_str_mv 2014-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/16879
Cardinali, Daniel Pedro; Vigo, Daniel Eduardo; Olivar, Natividad; Vidal, Maria Florencia; Brusco, Luis Ignacio; Melatonin therapy in patients with Alzheimer’s disease; Multidisciplinary Digital Publishing Institute; Antioxidants; 3; 2; 4-2014; 245-277
2076-3921
url http://hdl.handle.net/11336/16879
identifier_str_mv Cardinali, Daniel Pedro; Vigo, Daniel Eduardo; Olivar, Natividad; Vidal, Maria Florencia; Brusco, Luis Ignacio; Melatonin therapy in patients with Alzheimer’s disease; Multidisciplinary Digital Publishing Institute; Antioxidants; 3; 2; 4-2014; 245-277
2076-3921
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.mdpi.com/2076-3921/3/2/245
info:eu-repo/semantics/altIdentifier/doi/10.3390/antiox3020245
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269832943239168
score 13.13397

Publicaciones similares